Comparison of the effects of histamine and tolazoline on adenylate cyclase activity from guinea pig heart.
Both histamine and tolazoline (2-benzyl-2-imidazoline) stimulated particulate fractions of adenylate cyclase from guinea pig myocardium. Tolazoline was one-tenth as potent, and about two-thirds as active at maximally effective levels, as was histamine. Enhancement of cyclase activity by tolazoline was additive with that by isoproterenol, and the histamine and tolazoline concentration-response curves were parallel, suggesting that tolazoline acted at the same site as histamine. At maximally effective concentrations, tolazoline did not affect ATPase or cyclic AMP phosphodiesterase activities associated with the cyclase preparations. The H1-receptor antagonist mepyramine, and the H2 antagonist, burimamide, blocked stimulation of cyclase by tolazoline at one-tenth the molarity of agonist. Both antagonists were less effective vs. histamine stimulation of heart cyclase in particulate fractions or whole homogenates, with mepyramine being generally more potent. It is suggested that the molecular basis of the stimulatory effect of tolazoline on cardiac tissue may be histaminergic stimulation of adenylate cyclase. Furthermore, the lack of potency of burimamide as a histamine antagonist and its lack of specificity compared to mepyramine, at the subcellular level, indicate that histamine-responsive adenylate cyclase from heart may not be a satisfactory molecular model for the H2 receptor pharmacology of histamine in cardiac tissue.
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D001593:Benzyl Compounds / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005029:Ethylenediamines / Q000494:pharmacology; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006632:Histamine / Q000494:pharmacology*; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D009206:Myocardium / Q000201:enzymology*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D011955:Receptors, Drug / Q000187:drug effects; D013268:Stimulation, Chemical; D013890:Thiourea / Q000031:analogs & derivatives / Q000494:pharmacology; D014043:Tolazoline / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D001593:Benzyl Compounds; D005029:Ethylenediamines; D007093:Imidazoles; D011725:Pyridines; D011955:Receptors, Drug; D006632:Histamine; D014043:Tolazoline; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D000251:Adenosine Triphosphatases; D000262:Adenylyl Cyclases; D013890:Thiourea; D007545:Isoproterenol